Back to School: How biopharma can reboot drug development. Access exclusive analysis here

0821 ECP Amphista
BioCentury & Getty Images

Emerging Company Profile

Amphista: broadening the target space of protein degradation

Amphista raised $7.5M to test its targeted protein degradation platform in vivo

Amphista raised $7.5M to test its E3 ligase-independent targeted protein degraders in vivo.

Aug 22, 2020 | 12:49 AM GMT

Amphista aims to apply protein degradation to a broader set of targets and indications using an approach

Read the full 592 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers